内科外来におけるうつ病の頻度(各科領域におけるうつ病の実態と留意点)(第33回日本心身医学会総会)
スポンサーリンク
概要
- 論文の詳細を見る
This report addresses some issues relating to the prevalence rate of depressive disorders in primary care settings. It is very likely that the majority of people suffering from depression do consult the non-psychiatric practitioner. Many patients consult doctors for unrelated physical illness or for nonspecific somatic manifestations of depressive disorders. However, relevant epidemiological studies of these depressed patients are not sufficiently reliable because of methodological problems. Since 1972,we have participated in the WHO collaborative study on public health implications of depressed disorders. In collaboration with internists from two general hospitals, we have been able to estimate the prevalence rate of depressive disorders in outpatient clinics of these hospitals on two different occasions. In the first study (1977-1980), 831 cases were systematically selected from new ambulatory medical patients and interviewed by research psychiatrists using a screen from and the SADD schedule. Subsequently, 50 patients were found to have a depressive disorder (ICD-9). The prevalence rate of depressive disorders in these settings was 6%. The second study (1991) was part of a more extensive, ongoing research project organized by WHO, Using the "Two phase sampling design" (W. E. Deming) and using both the GHQ-12 and CIDI, we were able to screen 1043 ambulatory patients in one of above mentioned hospitals. The estimated prevalence rate of depressive disorders (DSM-III-R) was 5.4%. In this paper we questioned whether screening for depressive disorders has any value in general medical settings. The performance of a screening test instrument is measured by the predictive value of a positive or negative result. The predictive values of a positive result falls as the prevalence declines. Understanding this point is of practical importance. The conclusion of this paper is that depression questionnaires should not be routinely administered to ambulatory medical patients. There may be merit, however, to employ such assessment practice in selected circumstances and with a well-defined population.
- 日本心身医学会の論文
- 1993-02-01
著者
関連論文
- D-20 側頭葉てんかんと前頭葉機能
- てんかん患者における血清中結合形カルバマゼピン濃度の予測
- 小児てんかん患者における血清中非結合形カルバマゼピン濃度の予測
- 結合式による血清中非結合形バルプロ酸濃度の予測性の検討
- 健常成人におけるバルプロ酸反復投与時の体内動態
- 1D-7 側頭葉てんかん外科治療症例の記憶機能の変化について : 側頭葉切除側による比較
- D-12 側頭葉てんかん外科治療症例の高次脳機能の変化について : 器質例と非器質例による比較
- ID-23 バルプロ酸のTDM
- 抑うつ症状群が先行した悪性腫瘍の2例
- 反証可能な作業仮説としての臨床診断
- 内科外来におけるうつ病の頻度(各科領域におけるうつ病の実態と留意点)(第33回日本心身医学会総会)
- S-I-1 内科外来におけるうつ病の頻度(各科領域におけるうつ病の実態と留意点)
- うつ病(depression)は治るか
- Panic attack の記述現象学
- I-C-32 Panic attackの記述現象学(シンポジウム関連演題(Panic Disorder)III)
- Factors of Altered Drug Binding to Serum Proteins In Vivo: Studies with Valproic Acid.
- Pharmacokinetic Study in Acute Antiepileptic Intoxication Treated with Hemodialysis and Hemoperfusion.
- Binding parameters during repeated dosing of valproic acid in healthy adults.
- Examination on prediction of serum non-bonding valproic acid density by bond type.
- Prediction of the serum unconjugated valproic acid concentration using a combination parameter.
- Effects of non-bonding clearance on a combination parameter between valproic acid and serum protein.
- TDM of valproic acid(VPA).Study of an optimum blood sampling time.
- Valproic acid blood level prediction by population pharmacokinetics and Bayes estimation method.
- Prediction of non-bonding carbamazepine density in serum of infant patient of epilepsy.